炎症性肠病患者脂质异常概述
An overview of lipid abnormalities in patients with inflammatory bowel disease.
作者信息
Agouridis Aris P, Elisaf Moses, Milionis Haralampos J
机构信息
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
出版信息
Ann Gastroenterol. 2011;24(3):181-187.
Abstract
INFLAMMATORY BOWEL DISEASE (IBD) IS A CHRONIC INFLAMMATORY DISORDER WHICH ENCOMPASSES TWO FORMS OF INTESTINAL INFLAMMATION: ulcerative colitis and Crohn's disease. It is reported that inflammation, carotid intima media thickness, homocysteine and insulin resistance, parameters that are all associated with atherosclerosis, are increased in IBD. On the contrary, it seems that IBD patients exhibit low levels of low density lipoprotein cholesterol and total cholesterol. This review highlights the lipid profiles that occur in IBD patients and summarizes data of studies using regimens that may affect lipid metabolism in these patients.
摘要
炎症性肠病（IBD）是一种慢性炎症性疾病，包括两种肠道炎症形式：溃疡性结肠炎和克罗恩病。据报道，炎症、颈动脉内膜中层厚度、同型半胱氨酸和胰岛素抵抗（这些参数均与动脉粥样硬化相关）在IBD患者中有所增加。相反，IBD患者似乎低密度脂蛋白胆固醇和总胆固醇水平较低。本综述重点介绍了IBD患者的血脂情况，并总结了使用可能影响这些患者脂质代谢的治疗方案的研究数据。
相似文献
1
An overview of lipid abnormalities in patients with inflammatory bowel disease.
Ann Gastroenterol. 2011;24(3):181-187.
2
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.
Eur J Intern Med. 2017 Jan;37:83-89. doi: 10.1016/j.ejim.2016.10.004. Epub 2016 Oct 21.
3
Endothelial function and cardiovascular risk in active inflammatory bowel diseases.
J Crohns Colitis. 2013 Nov;7(10):e427-33. doi: 10.1016/j.crohns.2013.02.001. Epub 2013 Mar 7.
4
Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.
Dig Dis Sci. 2016 Mar;61(3):865-71. doi: 10.1007/s10620-015-3932-1. Epub 2015 Oct 29.
5
Low childhood high density lipoprotein cholesterol levels and subsequent risk for chronic inflammatory bowel disease.
Dig Liver Dis. 2018 Apr;50(4):348-352. doi: 10.1016/j.dld.2018.01.121. Epub 2018 Jan 31.
6
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
7
Evaluation of Early Atherosclerosis Markers in Patients with Inflammatory Bowel Disease.
Med Sci Monit. 2016 Oct 24;22:3943-3950. doi: 10.12659/msm.898160.
8
Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation.
Inflamm Bowel Dis. 2023 Apr 3;29(4):531-538. doi: 10.1093/ibd/izac100.
9
Increased pulse wave velocity and relationship with inflammation, insulin, and insulin resistance in inflammatory bowel disease.
Eur J Gastroenterol Hepatol. 2014 Jul;26(7):725-32. doi: 10.1097/MEG.0000000000000104.
10
Does carotid intima-media thickness increase in patients with inflammatory bowel disease?
Intest Res. 2014 Oct;12(4):293-8. doi: 10.5217/ir.2014.12.4.293. Epub 2014 Oct 27.
引用本文的文献
1
Low-Density Lipoprotein and High-Density Lipoprotein as Biomarkers for Inflammatory Bowel Disease Activity Assessment.
Int J Gen Med. 2025 Sep 4;18:5115-5125. doi: 10.2147/IJGM.S529428. eCollection 2025.
2
Transcriptional profiling identification of inflammatory signaling pathways in ulcerative colitis.
PLoS One. 2025 Sep 2;20(9):e0330332. doi: 10.1371/journal.pone.0330332. eCollection 2025.
3
Decline in Serum Lysophosphatidylcholine Species in Patients with Severe Inflammatory Bowel Disease.
J Clin Med. 2025 Aug 4;14(15):5485. doi: 10.3390/jcm14155485.
4
Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease.
Pathophysiology. 2025 Mar 25;32(2):13. doi: 10.3390/pathophysiology32020013.
5
Unveiling the influence of lipidomes on inflammatory bowel disease: a bidirectional mendelian randomization study.
BMC Gastroenterol. 2025 Apr 11;25(1):247. doi: 10.1186/s12876-025-03858-3.
6
Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives.
Adv Ther. 2025 May;42(5):2118-2134. doi: 10.1007/s12325-025-03154-2. Epub 2025 Mar 27.
7
To explore the causal association between the serum lipid profile and inflammatory bowel disease using bidirectional Mendelian randomisation analysis.
eGastroenterology. 2024 Jun 2;2(2):e100034. doi: 10.1136/egastro-2023-100034. eCollection 2024 Apr.
8
Comparative Evaluation of Lipid Profile, C-Reactive Protein and Paraoxonase-1 Activity in Dogs with Inflammatory Protein-Losing Enteropathy and Healthy Dogs.
Animals (Basel). 2024 Oct 29;14(21):3119. doi: 10.3390/ani14213119.
9
Microbiota in Mild Inflammatory Bowel Disease (IBD) Can Be Modulated by Beta-Glucans and Mannanoligosaccharides: A Randomized, Double-Blinded Study in Dogs.
Vet Sci. 2024 Aug 1;11(8):349. doi: 10.3390/vetsci11080349.
10
The molecular subtypes of autoimmune diseases.
Comput Struct Biotechnol J. 2024 Mar 28;23:1348-1363. doi: 10.1016/j.csbj.2024.03.026. eCollection 2024 Dec.
本文引用的文献
1
Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease.
Inflamm Bowel Dis. 2011 Oct;17(10):2162-8. doi: 10.1002/ibd.21585. Epub 2010 Dec 17.
2
Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.
Cancer. 2011 Apr 15;117(8):1640-8. doi: 10.1002/cncr.25731. Epub 2010 Nov 8.
3
Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease.
J Clin Lipidol. 2010 Nov-Dec;4(6):478-82. doi: 10.1016/j.jacl.2010.08.021. Epub 2010 Oct 28.
4
Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.
Clin Exp Rheumatol. 2010 Nov-Dec;28(6):880-3. Epub 2011 Jan 3.
5
Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study.
Eur J Gastroenterol Hepatol. 2010 May;22(5):602-6. doi: 10.1097/MEG.0b013e3283352d05.
6
Inflammatory bowel disease: review from the aspect of genetics.
J Gastroenterol. 2009;44(11):1097-108. doi: 10.1007/s00535-009-0141-8.
7
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
J Am Coll Cardiol. 2009 Aug 11;54(7):585-94. doi: 10.1016/j.jacc.2009.02.084.
8
The acute (cerebro)vascular effects of statins.
Anesth Analg. 2009 Aug;109(2):572-84. doi: 10.1213/ane.0b013e3181a85d0e.
9
The JUPITER trial: How will it change clinical practice?
Rev Cardiovasc Med. 2009 Spring;10(2):91-6.
10
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.
BMJ. 2009 Jun 30;338:b2376. doi: 10.1136/bmj.b2376.
Zotero 插件